ArticleInternational journal of surgery (London, England)2026
The safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: a prospective multicenter trial (CLASS-03a).
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A machine learning model for distinguishing gastric cancer from intestinal metaplasia in patients with psychological symptoms.Cancer causes & control : CCC · 2026Article
- Minimally invasive liver transplantation: technical evolution, evidence maturity, and translational boundaries.Updates in surgery · 2026Review
- Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues.Current oncology (Toronto, Ont.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The objective of this study was to ascertain the safety of laparoscopic distal D2 radical gastrectomy in treating gastric cancer patients after NAC with locally advanced disease (cT3-4a, N0/ +, M0) by evaluating postoperative complications. Study Design: A prospective, multicenter, single-arm clinical trial. Methods: This clinical trial was conducted at 14 hospital centers in China. Adults aged 18-75 years with histologically confirmed LAGC (cT3-4a, N0/ +, M0) were enrolled in the study. Participants received three cycles of administration of intravenous oxaliplatin (130 mg/m Results: A total of 153 patients who underwent NAC prior to laparoscopic D2 distal gastrectomy were included in the final analysis. The study reported a postoperative overall morbidity rate of 20.9% (95%CI: 15.2%-28.0%), with a postoperative mortality rate of 0%. Pneumonia is the most common complication (9.2%). Ten patients exhibited elevated levels of body fluid amylase without presenting any clinical symptoms or undergoing additional clinical intervention. The R0 resection rate was achieved at 100%. The rate of conversion to laparotomy was 1.3%. 9.2% of patients achieved pathological complete response (pCR) following NAC. The overall incidence of adverse effects after NAC was 20.3% (95%CI: 14.7%-27.3%). The most common grade 3-4 treatment-related adverse events during neoadjuvant treatment were a decrease in platelet count and vomiting, each occurring in 0.7% of patients. Conclusion: The laparoscopic distal D2 radical gastrectomy demonstrated a favorable safety profile in the treatment of gastric cancer patients with advanced disease (cT3-4a, N0/ +, M0) following NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.